Body Fat Disorder Clinical Trial
— TOPSOfficial title:
The Effects of Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction
Verified date | June 2017 |
Source | Zeltiq Aesthetics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate the effects of tissue optimization before and during cryolipolysis procedures on the outcome of non-invasive fat reduction using the ZELTIQ System.
Status | Completed |
Enrollment | 19 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria 1. Male or female subjects > 18 years of age and < 65 years of age. 2. Subject has clearly visible fat on intended treatment area, which in the investigator's opinion, may benefit from the treatment(s). 3. Subject has not had weight change exceeding 10 pounds in the preceding month. 4. Subject with body mass index (BMI) less than 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. 5. Subject agrees to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study. 6. Subject has read and signed a written informed consent form. Exclusion Criteria 1. Subject presents a significant asymmetry of intended treatment areas. 2. Subject has had a surgical procedure(s) in the area of intended treatment in the past 5 years.. 3. Subject has had an invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment in the past 5 years. 4. Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 6 months. 5. Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. 6. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. 7. Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. 8. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. 9. Subject is taking or has taken diet pills or weight control supplements within the past month. 10. Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). 11. Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system. 12. Subject is pregnant or intending to become pregnant in the next 5 months. 13. Subject is lactating or has been lactating in the past 6 months. 14. Subject has a history of hernia in the areas to be treated. 15. Subject is unable or unwilling to comply with the study requirements. 16. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 17. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject. |
Country | Name | City | State |
---|---|---|---|
United States | Innovation Research Center | Pleasanton | California |
Lead Sponsor | Collaborator |
---|---|
Zeltiq Aesthetics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy | Effectiveness: Comparison of pre- and 16-week post-treatment photographs of the treatment areas to select the side with greater improvement. | 16 weeks post final treatment | |
Secondary | Photographs pre and 8-week post | Comparison of pre- and 8-week post-treatment photographs of the treatment areas to select the side with greater improvement. | 8 weeks post final treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01686841 -
A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production
|
N/A | |
Completed |
NCT04340388 -
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
|
Phase 4 | |
Completed |
NCT02554760 -
Bilateral; Flank Study With Crown Cooling Insert
|
N/A | |
Completed |
NCT04142450 -
CoolSculpting® the Upper Arms and Inner Thighs in Participants of Chinese Descent (XinCOOL)
|
N/A | |
Active, not recruiting |
NCT03304925 -
CoolSculpting the Flanks
|
N/A | |
Completed |
NCT02941146 -
DualSculpting the Abdomen Using CoolSculpting
|
N/A | |
Completed |
NCT01859091 -
Pilot Study on the Submental Area
|
N/A | |
Completed |
NCT01763775 -
Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)
|
N/A | |
Completed |
NCT05558488 -
The Effect of a Meatless,Keto Restrictive Diet on Body Composition,Strength Capacity,Oxidative Stress,Immune Response
|
N/A | |
Completed |
NCT03738891 -
CoolSculpting and EMS for the Abdomen
|
N/A | |
Withdrawn |
NCT04199806 -
Retrospective Study of Patient Surveys
|
N/A | |
Completed |
NCT01296048 -
Clinical Test for Transtek Glass Body Analyzer
|
N/A | |
Completed |
NCT02324816 -
Fat Layer Reduction in the Lateral Thighs Using CoolSculpting
|
N/A | |
Recruiting |
NCT04876118 -
Effects on Cellulite Appearance
|
N/A | |
Completed |
NCT02298322 -
Subcutaneous Fat Reduction in the Submental Area
|
N/A | |
Completed |
NCT01600638 -
Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature
|
N/A | |
Completed |
NCT03510598 -
Submental Study (Sequential Treatment Approach)
|
Phase 4 | |
Completed |
NCT01814007 -
Multiple CoolSculpting Treatment Study
|
N/A | |
Completed |
NCT01579487 -
Extended Follow-Up Study for Subjects Who Participated in 2010 Study
|
N/A | |
Enrolling by invitation |
NCT04506307 -
CoolSculpting System
|
N/A |